Results 161 to 170 of about 2,524 (195)

Parent Perspectives on Nirsevimab for Their Newborn

Pediatrics
BACKGROUND In 2023, nirsevimab, a monoclonal antibody against respiratory syncytial virus (RSV), was approved in the United States to be given to infants to prevent bronchiolitis, a leading cause of pediatric hospitalizations.
Sarah, Hinderstein, Elena, Aragona, Jaspreet, Loyal   +2 more
openaire   +2 more sources

Nirsevimab: A Review

Pediatric Allergy, Immunology, and Pulmonology
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in people of all ages and is the leading cause of hospitalization among infants in the United States. The year 2023 was exciting for RSV prevention. The Food and Drug Administration (FDA) approved 3 new tools for preventing severe lower respiratory tract RSV ...
openaire   +2 more sources

Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children

Pediatrics
BACKGROUND AND OBJECTIVES Immunocompromised children may have increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI), potentially leading to prolonged hospitalization, intensive care, and death.
Joseph, Domachowske, Ulrika Wählby, Hamrén, Irfana, Banu, Roberta, Baronio, Bhanu, Basavaraju, Anthonet, Koen, Amanda, Leach, Vaishali S, Mankad, Pia S, Pannaraj, Pere, Soler-Palacin, Therese, Takas, Masaaki, Mori, Tonya, Villafana   +12 more
openaire   +2 more sources

Balanced on the Biggest Wave: Nirsevimab for Newborns

Neonatal Network
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete
Christopher, McPherson, Christine R, Lockowitz, Jason G, Newland   +2 more
openaire   +2 more sources

Nirsevimab Administration During the Birth Hospitalization

Hospital Pediatrics
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of newborn hospitalization. In July 2023, nirsevimab, a monoclonal antibody to protect infants against RSV and reduce severe illness, was approved. Nirsevimab is the newest birth hospitalization immunization.
Shayda, Daneshvari, Philip, Lee, Sheri L, Nemerofsky   +2 more
openaire   +2 more sources

Nirsevimab-alip

Clinical Therapeutics, 2023
openaire   +4 more sources

Practical Application of Nirsevimab Recommendations for Infants and Toddlers

Journal of Pediatric Health Care
Respiratory syncytial virus (RSV) is a common respiratory tract infection that causes bronchiolitis and pneumonia in infants and children. It is the leading cause of hospitalization of infants in the United States. Nirsevimab is a long-acting monoclonal antibody recommended for the prevention of severe disease in all infants under 8 months of age and ...
Carol Risko Radcliffe, Gabriella Akkawi, Rebecca A. Carson   +2 more
openaire   +2 more sources

Impact of nirsevimab immunization on admissions at a tertiary hospital

Enfermedades infecciosas y microbiologia clinica (English ed.)
The efficacy of nirsevimab for the prevention of respiratory syncytial virus (RSV) infection has shown good real-life results. The objective was to investigate the impact of a nirsevimab immunisation strategy on admissions due to RSV and bronchiolitis caused by other viruses in a tertiary care hospital.Cohort study comparing the cumulative incidence of
Manuel, Oltra-Benavent, Raquel, Suay-Romero, Eva, Muro-Díaz, Pablo Javier, Taberner-Pérez, María Belén, Ferrer-Lorente, Juan Pablo, Ferrer-González, María, Garcés-Sánchez   +6 more
openaire   +2 more sources

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

Pediatrics
BACKGROUND Data describing respiratory syncytial virus (RSV) neutralizing antibody (nAb) levels for nirsevimab, a recently approved, extended half-life, anti-RSV fusion protein (F protein) monoclonal antibody, relative to the previous standard of care, palivizumab ...
Deidre, Wilkins, Ulrika, Wählby Hamrén, Yue, Chang, Lindsay E, Clegg, Joseph, Domachowske, Janet A, Englund, William J, Muller, Amanda, Leach, Elizabeth J, Kelly, Tonya, Villafana   +9 more
openaire   +2 more sources

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

New England Journal of Medicine, 2022
William J Muller, Michael E Abram, Amanda Leach   +2 more
exaly